Interaction between neuromelanin and alpha-synuclein in Parkinson’s disease

Biomolecules

Volumn 5, Issue 2, 2015, Pages 1122-1142

  Xu, Shengli ^a,b   Chan, Piu ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

Alpha synuclein; Neuromelanin; Oxidative stress; Parkinson s disease

Indexed keywords

ALPHA SYNUCLEIN; NEUROMELANIN; REACTIVE OXYGEN METABOLITE; MELANIN;

BIOSYNTHESIS; CYTOTOXICITY; DEGENERATIVE DISEASE; ENVIRONMENTAL CHANGE; ENZYME ACTIVITY; GENE DUPLICATION; GENE OVEREXPRESSION; HUMAN; MISSENSE MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; MELANINS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 85012094006     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5021122     Document Type: Review

References (162)

1. Olanow, C. W.; Tatton, W. G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22, 123-144.
2. Sulzer, D.; Surmeier, D. J. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 2013, 28, 41-50.
3. Fahn, S.; Sulzer, D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004, 1, 139-154.
4. Poewe, W.; Antonini, A.; Zijlmans, J. C.; Burkhard, P. R.; Vingerhoets, F. Levodopa in the treatment of Parkinson's disease: An old drug still going strong. Clin. Interv. Aging 2010, 7, 229-238.
5. Gonera, E. G.; Van't Hof, M.; Berger, H. J.; van Weel, C.; Horstink, M. W. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov. Disord. 1997, 12, 871-876.
6. Ziemssen, T.; Reichmann, H. Non-motor dysfunction in Parkinson's disease. Park. Relat. Disord. 2007, 13, 323-332.
7. Maass, A.; Reichmann, H. Sleep and non-motor symptoms in Parkinson's disease. J. Neural Transm. 2013, 120, 565-569.
8. Jenner, P.; Morris, H. R.; Robbins, T. W.; Goedert, M.; Hardy, J.; Ben-Shlomo, Y.; Bolam, P.; Burn, D.; Hindle, J. V.; Brooks, D. Parkinson's disease-The debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J. Parkinsons Dis. 2013, 3, 1-11.
9. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276, 2045-2047.
10. Singleton, A. B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; et al. β-Synuclein locus triplication causes Parkinson's disease. Science 2003, doi: 10. 1126/science. 1090278.
11. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44, 601-607.
12. Westbroek, W.; Gustafson, A. M.; Sidransky, E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 2011, 17, 485-493.
13. Gouider-Khouja, N.; Larnaout, A.; Amouri, R.; Sfar, S.; Belal, S.; Ben Hamida, C.; Ben Hamida, M.; Hattori, N.; Mizuno, Y.; Hentati, F. Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Park. Relat. Disord. 2003, 9, 247-251.
14. Bonifati, V.; Rizzu, P.; van Baren, M. J.; Schaap, O.; Breedveld, G. J.; Krieger, E.; Dekker, M. C.; Squitieri, F.; Ibanez, P.; Joosse, M.; et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256-259.
15. Valente, E. M.; Abou-Sleiman, P. M.; Caputo, V.; Muqit, M. M.; Harvey, K.; Gispert, S.; Ali, Z.; del Turco, D.; Bentivoglio, A. R.; Healy, D. G.; et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304, 1158-1160.
16. Hamza, T. H.; Zabetian, C. P.; Tenesa, A.; Laederach, A.; Montimurro, J.; Yearout, D.; Kay, D. M.; Doheny, K. F.; Paschall, J.; Pugh, E.; et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42, 781-785.
17. Skipper, L.; Wilkes, K.; Toft, M.; Baker, M.; Lincoln, S.; Hulihan, M.; Ross, O. A.; Hutton, M.; Aasly, J.; Farrer, M. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 2004, 75, 669-677.
18. Jensen, P. H.; Nielsen, M. S.; Jakes, R.; Dotti, C. G.; Goedert, M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 1998, 273, 26292-26294.
19. Farrer, M.; Wavrant-De Vrieze, F.; Crook, R.; Boles, L.; Perez-Tur, J.; Hardy, J.; Johnson, W. G.; Steele, J.; Maraganore, D.; Gwinn, K.; et al. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann. Neurol. 1998, 43, 394-397.
20. Zarranz, J. J.; Alegre, J.; Gómez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164-173.
21. Proukakis, C.; Dudzik, C. G.; Brier, T.; MacKay, D. S.; Cooper, J. M.; Millhauser, G. L.; Houlden, H.; Schapira, A. H. A novel β-synuclein missense mutation in Parkinson disease. Neurology 2013, 80, 1062-1064.
22. Kiely, A. P.; Asi, Y. T.; Kara, E.; Limousin, P.; Ling, H.; Lewis, P.; Proukakis, C.; Quinn, N.; Lees, A. J.; Hardy, J.; et al. β-Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 2013, 125, 753-769.
23. Pasanen, P.; Myllykangas, L.; Siitonen, M.; Raunio, A.; Kaakkola, S.; Lyytinen, J.; Tienari, P. J.; Pöyhönen, M.; Paetau, A. Novel β-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 2014, 35, 2180. e1-2180. e5.
24. Reeve, A.; Simcox, E.; Turnbull, D. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? Ageing Res. Rev. 2014, 14, 19-30.
25. Subramaniam, S. R.; Chesselet, M. F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 2013, 106-107, 17-32.
26. Mosharov, E. V.; Larsen, K. E.; Kanter, E.; Phillips, K. A.; Wilson, K.; Schmitz, Y.; Krantz, D. E.; Kobayashi, K.; Edwards, R. H.; Sulzer, D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein cause selective death of substantia nigra neurons. Neuron 2009, 62, 218-229.
27. Muñoz, P.; Huenchuguala, S.; Paris, I.; Segura-Aguilar, J. Dopamine oxidation and autophagy. Park. Dis. 2012, doi: 10. 1155/2012/920953.
28. Sulzer, D.; Mosharov, E.; Talloczy, Z.; Zucca, F. A.; Simon, J. D.; Zecca, L. Neuronal pigmented autophagic vacuoles: Lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 2008, 106, 24-36.
29. Xuan, Q.; Xu, S. L.; Lu, D. H.; Yu, S.; Zhou, M.; Uéda, K.; Cui, Y. Q.; Zhang, B. Y.; Chan, P. Increased expression of β-synuclein in aged human brain associated with neuromelanin accumulation. J. Neural Transm. 2011, 118, 1575-1583.
30. Zhang, W.; Phillips, K.; Wielgus, A. R.; Liu, J.; Albertini, A.; Zucca, F. A.; Faust, R.; Qian, S. Y.; Miller, D. S.; Chignell, C. F.; et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: Implications for progression of Parkinson's disease. Neurotox. Res. 2011, 19, 63-72.
31. Chartier-Harlin, M. C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364, 1167-1169.
32. Byers, B.; Cord, B.; Nguyen, H. N.; Schüle, B.; Fenno, L.; Lee, P. C.; Deisseroth, K.; Langston, J. W.; Pera, R. R.; Palmer, T. D. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate β-synuclein and are susceptible to oxidative stress. PLoS ONE 2011, 6, e26159.
33. Kanda, S.; Bishop, J. F.; Eglitis, M. A.; Yang, Y.; Mouradian, M. M. Enhanced viability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000, 97, 279-284.
34. Narhi, L.; Wood, S. J.; Steavenson, S.; Jiang, Y.; Wu, G. M.; Anafi, D.; Kaufman, S. A.; Martin, F.; Sitney, K.; Denis, P.; et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 1999, 274, 9843-9846.
35. Khalaf, O.; Fauvet, B.; Oueslati, A.; Dikiy, I.; Mahul-Mellier, A. L.; Ruggeri, F. S.; Mbefo, M.; Vercruysse, F.; Dietler, G.; Lee, S. J.; et al. The H50Q mutation enhances β-synuclein aggregation, secretion and toxicity. J. Biol. Chem. 2014, 289, 21856-21876.
36. Rutherford, N. J.; Moore, B. D.; Golde, T. E.; Giasson, B. I. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of β-synuclein. J. Neurochem. 2014, 131, 859-867.
37. Ghosh, D.; Sahay, S.; Ranjan, P.; Salot, S.; Mohite, G. M.; Singh, P. K.; Dwivedi, S.; Carvalho, E.; Banerjee, R.; Kumar, A.; et al. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates β-synuclein aggregation and membrane binding. Biochemistry 2014, 53, 6419-6421.
38. Yan, J. Q.; Yuan, Y. H.; Gao, Y. N.; Huang, J. Y.; Ma, K. L.; Gao, Y.; Zhang, W. Q.; Guo, X. F.; Chen, N. H. Overexpression of human E46K mutant β-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway. Mol. Neurobiol. 2014, 50, 685-701.
39. Ramanan, V. K.; Saykin, A. J. Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am. J. Neurodegener. Dis. 2013, 18, 145-175.
40. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41, 1303-1307.
41. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. β-Synuclein in Lewy bodies. Nature 1997, 388, 839-840.
42. Zhang, N. Y.; Tang, Z.; Liu, C. W. β-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: Understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 2008, 283, 20288-20298.
43. Lashuel, H. A.; Grillo-Bosch, D. In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein. Methods Mol. Biol. 2005, 299, 19-33.
44. Cole, N. B.; Murphy, D. D.; Lebowitz, J.; Di Noto, L.; Levine, R. L.; Nussbaum, R. L. Metal-catalyzed oxidation of alpha-synuclein: Helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 2005, 280, 9678-9690.
45. Wakabayashi, K.; Tanji, K.; Mori, F.; Takahashi, H. The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27, 494-506.
46. Fagerqvist, T.; Lindström, V.; Nordström, E.; Lord, A.; Tucker, S. M.; Su, X.; Sahlin, C.; Kasrayan, A.; Andersson, J.; Welander, H.; et al. Monoclonal antibodies selective for β-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and β-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 2013, 126, 131-144.
47. Lee, H. J.; Lee, S. J. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 2002, 277, 48976-48983.
48. Lindström, V.; Fagerqvist, T.; Nordström, E.; Eriksson, F.; Lord, A.; Tucker, S.; Andersson, J.; Johannesson, M.; Schell, H.; Kahle, P. J.; et al. Immunotherapy targeting β-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] β-synuclein mice. Neurobiol. Dis. 2014, 69, 134-143.
49. Lavedan, C. The synuclein family. Genome Res. 1998, 8, 871-880.
50. Maroteaux, L.; Campanelli, J. T.; Scheller, R. H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8, 2804-2815.
51. Bendor, J. T.; Logan, T. P.; Edwards, R. H. The function of β-synuclein. Neuron 2013, 79, 1044-1066.
52. George, J. M. The synucleins. Genome Biol. 2002, doi: 10. 1186/gb-2001-3-1-reviews3002.
53. Bartels, T.; Choi, J. G.; Selkoe, D. J. β-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477, 107-110.
54. Wang, W.; Perovic, I.; Chittuluru, J.; Kaganovich, A.; Nguyen, L. T.; Liao, J.; Auclair, J. R.; Johnson, D.; Landeru, A.; Simorellis, A. K.; et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 2011, 108, 17797-17802.
55. Conway, K. A.; Lee, S. J.; Rochet, J. C.; Ding, T. T.; Harper, J. D.; Williamson, R. E.; Lansbury, P. T. Accelerated oligomerization by Parkinson's disease linked β-synuclein mutants. Ann. NY Acad. Sci. 2000, 920, 42-45.
56. Conway, K. A.; Rochet, J. C.; Bieganski, R. M.; Lansbury, P. T., Jr. Kinetic stabilization of the β-synuclein protofibril by a dopamine-β-Synuclein adduct. Science 2001, 294, 1346-1349.
57. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M. S.; Shen, J.; Takio, K.; Iwatsubo, T. β-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160-164.
58. Jethva, P. N.; Kardani, J. R.; Roy, I. Modulation of β-synuclein aggregation by dopamine in the presence of MPTP and its metabolite. FEBS J. 2011, 278, 1688-1698.
59. Jenco, J. M.; Rawlingson, A.; Daniels, B.; Morris, A. J. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha-and beta-synucleins. Biochemistry 1998, 37, 4901-4909.
60. Murphy, D. D.; Rueter, S. M.; Trojanowski, J. Q.; Lee, V. M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 2000, 20, 3214-3220.
61. Cabin, D. E.; Shimazu, K.; Murphy, D.; Cole, N. B.; Gottschalk, W.; McIlwain, K. L.; Orrison, B.; Chen, A.; Ellis, C. E.; Paylor, R.; et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 2002, 22, 8797-8807.
62. Chandra, S.; Fornai, F.; Kwon, H. B.; Yazdani, U.; Atasoy, D.; Liu, X.; Hammer, R. E.; Battaglia, G.; German, D. C.; Castillo, P. E.; et al. Double-knockout mice for alpha-and beta-synucleins: Effect on synaptic functions. Proc. Natl. Acad. Sci. USA 2004, 101, 14966-14971.
63. Chen, R. H.; Wislet-Gendebien, S.; Samuel, F.; Visanji, N. P.; Zhang, G.; Marsilio, D.; Langman, T.; Fraser, P. E.; Tandon, A. β-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J. Biol. Chem. 2013, 288, 7438-7449.
64. Martin, L. J.; Pan, Y.; Price, A. C.; Sterling, W.; Copeland, N. G.; Jenkins, N. A.; Price, D. L.; Lee, M. K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006, 26, 41-50.
65. Devi, L.; Raghavendran, V.; Prabhu, B. M.; Avadhani, N. G.; Anandatheerthavarada, H. K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283, 9089-9100.
66. Liu, G.; Zhang, C.; Yin, J.; Li, X.; Cheng, F.; Li, Y.; Yang, H.; Uéda, K.; Chan, P.; Yu, S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454, 187-192.
67. Chinta, S. J.; Mallajosyula, J. K.; Rane, A.; Andersen, J. K. Mitochondrial β-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010, 486, 235-239.
68. Nakamura, K.; Nemani, V. M.; Azarbal, F.; Skibinski, G.; Levy, J. M.; Egami, K.; Munishkina, L.; Zhang, J.; Gardner, B.; Wakabayashi, J.; et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011, 286, 20710-20726.
69. Cooper, A. A.; Gitler, A. D.; Cashikar, A.; Haynes, C. M.; Hill, K. J.; Bhullar, B.; Liu, K.; Xu, K.; Strathearn, K. E.; Liu, F.; et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313, 324-328.
70. Gitler, A. D.; Bevis, B. J.; Shorter, J.; Strathearn, K. E.; Hamamichi, S.; Su, L. J.; Caldwell, K. A.; Caldwell, G. A.; Rochet, J. C.; McCaffery, J. M.; et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105, 145-150.
71. Thayanidhi, N.; Helm, J. R.; Nycz, D. C.; Bentley, M.; Liang, Y.; Hay, J. C. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell. 2010, 21, 1850-1863.
72. Ebrahimi-Fakhari, D.; Cantuti-Castelvetri, I.; Fan, Z.; Rockenstein, E.; Masliah, E.; Hyman, B. T.; McLean, P. J.; Unni, V. K. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of β-synuclein. J. Neurosci. 2011, 31, 14508-14520.
73. Volles, M. J.; Lee, S. J.; Rochet, J. C.; Shtilerman, M. D.; Ding, T. T.; Kessler, J. C.; Lansbury, P. T., Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 2001, 40, 7812-7819.
74. Dias, V.; Junn, E.; Mouradian, M. M. The role of oxidative stress in Parkinson's disease. J. Park. Dis. 2013, 3, 461-491.
75. Oueslati, A.; Ximerakis, M.; Vekrellis, K. Protein transmission, seeding and degradation: key steps for β-synuclein prion-like propagation. Exp. Neurobiol. 2014, 23, 324-336.
76. Surgucheva, I.; Newell, K. L.; Burns, J.; Surguchov, A. New α-and β-synuclein immunopathological lesions in human brain. Acta Neuropathol Commun. 2014, doi: 10. 1186/s40478-014-0132-8.
77. Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de Laat, R.; Banducci, K.; Caccavello, R. J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281, 29739-29752.
78. Kahle, P. J.; Neumann, M.; Ozmen, L.; Muller, V.; Jacobsen, H.; Schindzielorz, A.; Okochi, M.; Leimer, U.; van der Putten, H.; Probst, A.; et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 2000, 20, 6365-6373.
79. Takahashi, T.; Yamashita, H.; Nagano, Y.; Nakamura, T.; Ohmori, H.; Avraham, H.; Avraham, S.; Yasuda, M.; Matsumoto, M. Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation. J. Biol. Chem. 2003, 278, 42225-42233.
80. Azeredo da Silveira, S.; Schneider, B. L.; Cifuentes-Diaz, C.; Sage, D.; Abbas-Terki, T.; Iwatsubo, T.; Unser, M.; Aebischer, P. Phosphorylation does not prompt, nor prevent, the formation of β-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18, 872-887.
81. McFarland, N. R.; Fan, Z.; Xu, K.; Schwarzschild, M. A.; Feany, M. B.; Hyman, B. T.; McLean, P. J. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J. Neuropathol. Exp. Neurol. 2009, 68, 515-524.
82. Sato, H.; Kato, T.; Arawaka, S. The role of Ser129 phosphorylation of β-synuclein in neurodegeneration of Parkinson's disease: Areview of in vivo models. Rev. Neurosci. 2013, 24, 115-123.
83. Waxman, E. A.; Giasson, B. I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 2008, 67, 402-416.
84. Mbefo, M. K.; Paleologou, K. E.; Boucharaba, A.; Oueslati, A.; Schell, H.; Fournier, M.; Olschewski, D.; Yin, G.; Zweckstetter, M.; Masliah, E.; et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 2010, 285, 2807-2822.
85. Waxman, E. A.; Giasson, B. I. Induction of intracellular tau aggregation is promoted by β-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J. Neurosci. 2011, 31, 7604-7618.
86. Tenreiro, S.; Eckermann, K.; Outeiro, T. F. Protein phosphorylation in neurodegeneration: Friend or foe? Front. Mol. Neurosci. 2014, doi: 10. 3389/fnmol. 2014. 00042.
87. Oueslati, A.; Schneider, B. L.; Aebischer, P.; Lashuel, H. A. Polo-like kinase 2 regulates selective autophagic β-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. USA 2013, 110, E3945-E3954.
88. Rott, R.; Szargel, R.; Shani, V.; Bisharat, S.; Engelender, S. β-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2014, 13, 630-637.
89. Haj-Yahya, M.; Fauvet, B.; Herman-Bachinsky, Y.; Hejjaoui, M.; Bavikar, S. N.; Karthikeyan, S. V.; Ciechanover, A.; Lashuel, H. A.; Brik, A. Synthetic polyubiquitinated β-synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc. Natl. Acad. Sci. USA 2013, 110, 17726-17731.
90. Tofaris, G. K.; Garcia Reitböck, P.; Humby, T.; Lambourne, S. L.; O'Connell, M.; Ghetti, B.; Gossage, H.; Emson, P. C.; Wilkinson, L. S.; Goedert, M.; et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human β-synuclein (1-120): Implications for Lewy body disorders. J. Neurosci. 2006, 26, 3942-3950.
91. Souza, J. M.; Giasson, B. I.; Chen, Q.; Lee, V. M.; Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275, 18344-18349.
92. Vila, M.; Vukosavic, S.; Jackson-Lewis, V.; Neystat, M.; Jakowec, M.; Przedborski, S. β-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74, 721-729.
93. Hsu, L. J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157, 401-410.
94. Hashimoto, M.; Takeda, A.; Hsu, L. J.; Takenouchi, T.; Masliah, E. Role of cytochrome C as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 1999, 274, 28849-28852.
95. Levin, J.; Högen, T.; Hillmer, A. S.; Bader, B.; Schmidt, F.; Kamp, F.; Kretzschmar, H. A.; Bötzel, K.; Giese, A. Generation of ferric iron links oxidative stress to β-synuclein oligomer formation. J. Park. Dis. 2011, 1, 205-216.
96. Kim, K. S.; Choi, S. Y.; Kwon, H. Y.; Won, M. H.; Kang, T. C.; Kang, J. H. Aggregation of β-synuclein induced by the Cu, Zn-superoxide dismutase and hydrogen peroxide system. Free Radic. Biol. Med. 2002, 32, 544-550.
97. Goers, J.; Manning-Bog, A. B.; McCormack, A. L.; Millett, I. S.; Doniach, S.; di Monte, D. A.; Uversky, V. N.; Fink, A. L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003, 42, 8465-8471.
98. Xu, S.; Zhou, M.; Yu, S.; Cai, Y.; Zhang, A.; Uéda, K.; Chan, P. Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun. 2006, 342, 330-335.
99. Zhou, M.; Xu, S.; Mi, J.; Uéda, K.; Chan, P. Nuclear translocation of alpha-synuclein increases susceptibility of MES23. 5 cells to oxidative stress. Brain Res. 2013, 1500, 19-27.
100. Hasegawa, T.; Matsuzaki-Kobayashi, M.; Takeda, A.; Sugeno, N.; Kikuchi, A.; Furukawa, K.; Perry, G.; Smith, M. A.; Itoyama, Y. Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease. FEBS Lett. 2006, 580, 2147-2152.
101. Yu, S.; Uéda, K.; Chan, P. β-Synuclein and dopamine metabolism. Mol. Neurobiol. 2005, 31, 243-254.
102. Schlüter, O. M.; Fornai, F.; Alessandrí, M. G.; Takamori, S.; Geppert, M.; Jahn, R.; Südhof, T. C. Role of alpha-synuclein in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2003, 118, 985-1002.
103. Zhou, M.; Xu, S. L.; Chen, B. Dual effects of different concentrations of alpha-synuclein on the neurotoxicity of 6-hydroxydopamine in SH-SY5Y cells. Sheng Li Xue Bao 2009, 61, 324-330.
104. Thomas, B.; Mandir, A. S.; West, N.; Liu, Y.; Andrabi, S. A.; Stirling, W.; Dawson, V. L.; Dawson, T. M.; Lee, M. K. Resistance to MPTP-neurotoxicity in β-synuclein knockout mice is complemented by human β-synuclein and associated with increased β-synuclein and Akt activation. PLoS ONE 2011, 6, e16706.
105. Klivenyi, P.; Siwek, D.; Gardian, G.; Yang, L.; Starkov, A.; Cleren, C.; Ferrante, R. J.; Kowall, N. W.; Abeliovich, A.; Beal, M. F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006, 21, 541-548.
106. Duffy, P. E.; Tennyson, V. M. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J. Neuropthol. Exp. Neurol. 1965, 24, 398-414.
107. Fenichel, G. M.; Bazelon, M. Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 1968, 18, 817-820.
108. Cheng, J.; Moss, S. C.; Eisner, M. X-ray characterization of melanins-II. Pigment Cell Res. 1994, 7, 263-273.
109. Haavik, J. L-DOPA is a substrate for tyrosine hydroxylase. J. Neurochem. 1997, 69, 1720-1728.
110. Okun, M. R. The role of peroxidase in neuromelanin synthesis: A review. Physiol. Chem. Phys. Med. NMR 1997, 29, 15-22.
111. Sulzer, D.; Bogulavsky, J.; Larsen, K. E.; Behr, G.; Karatekin, E.; Kleinman, M. H.; Turro, N.; Krantz, D.; Edwards, R. H.; Greene, L. A.; et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 2000, 97, 11869-11874.
112. D'Amato, R. J.; Lipman, Z. P.; Snyder, S. H. Selectivity of the parkinsonian neurotoxin MPTP: Toxic metabolite MPP+ binds to neuromelanin. Science 1986, 231, 987-989.
113. Lindquist, N. G.; Larsson, B. S.; Lydén-Sokolowski, A. Neuromelanin and its possible protective and destructive properties. Pigment Cell Res. 1987, 1, 133-136.
114. Zecca, L.; Pietra, R.; Goj, C.; Mecacci, C.; Radice, D.; Sabbioni, E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 1994, 62, 1097-1101.
115. Fornstedt, B.; Brun, A.; Rosengren, E.; Carlsson, A. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. Park. Dis. Dement Sect. 1989, 1, 279-295.
116. Wilczok, T.; Stepien, K.; Dzierzega-Lecznar, A.; Zajdel, A.; Wilczok, A. Model neuromelanins as antioxidative agents during lipid peroxidation. Neurotox. Res. 1999, 1, 141-147.
117. Shamoto-Nagai, M.; Maruyama, W.; Akao, Y.; Osawa, T.; Tribl, F.; Gerlach, M.; Zucca, F. A.; Zecca, L.; Riederer, P.; Naoi, M. Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J. Neural Transm. 2004, 111, 1253-1265.
118. Zareba, M.; Bober, A.; Korytowski, W.; Zecca, L.; Sarna, T. The effect of a synthetic neruomelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta 1995, 1271, 343-348.
119. Wakamatsu, K.; Fujikawa, K.; Zucca, F. A.; Zecca, L.; Ito, S. The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 2003, 86, 1015-1023.
120. Ito, S.; Wakamatsu, K. Chemical degradation of melanins: Application to identification of dopamine-melanin. Pigment Cell Res. 1998, 11, 120-126.
121. Halliday, G. M.; Ophof, A.; Broe, M.; Jensen, P. H.; Kettle, E.; Fedorow, H.; Cartwright, M. I.; Griffiths, F. M.; Shepherd, C. E.; Double, K. L. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005, 128, 2654-2664.
122. Zhang, W.; Yan, Z. F.; Gao, J. H.; Sun, L.; Huang, X. Y.; Liu, Z.; Yu, S. Y.; Cao, C. J.; Zuo, L. J.; Chen, Z. J.; et al. Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol. Neurobiol. 2014, 49, 1153-1165.
123. Wilms, H.; Rosenstiel, P.; Sievers, J.; Deuschl, G.; Zecca, L.; Lucius, R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. FASEB J. 2003, 17, 500-502.
124. Zucca, F. A.; Basso, E.; Cupaioli, F. A.; Ferrari, E.; Sulzer, D.; Casella, L.; Zecca, L. Neuromelanin of the human substantia nigra: An update. Neurotox. Res. 2014, 25, 13-23.
125. Ostergren, A.; Annas, A.; Skog, K.; Lindquist, N. G.; Brittebo, E. B. Longterm retention of neurotoxic beta-carbolines in brain neuromelanin. J. Neural Transm. 2004, 111, 141-157.
126. Lindquist, N. G.; Larsson, B. S.; Lyden-Sokolowski, A. Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin. Neurosci. Lett. 1988, 93, 1-6.
127. Zucca, F. A.; Giaveri, G.; Gallorini, M.; Albertini, A.; Toscani, M.; Pezzoli, G.; Lucius, R.; Wilms, H.; Sulzer, D.; Ito, S.; et al. The neuromelanin of human substantia nigra: Physiological and pathogenic aspects. Pigment Cell Res. 2004, 17, 610-617.
128. Zecca, L.; Mecacci, C.; Seraglia, R.; Parati, E. The chemical characterization of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta 1992, 1138, 6-10.
129. Zecca, L.; Costi, P.; Mecacci, C.; Ito, S.; Terreni, M.; Sonnino, S. Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 2000, 74, 1758-1765.
130. Aime, S.; Fasano, M.; Bergamasco, B.; Lopiano, L.; Valente, G. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J. Neurochem. 1994, 62, 369-371.
131. Barden, H. The histochemical relationship of neuromelanin and lipofuscin. J. Neuropathol. Exp. Neurol. 1969, 28, 419-441.
132. Swartz, H. M.; Sarna, T.; Zecca, L. Modulation by neuromelanin of the availability and reactivity of metal ions. Ann. Neurol. 1992, 32, S69-S75.
133. Zucca, F. A.; Bellei, C.; Giannelli, S.; Terreni, M. R.; Gallorini, M.; Rizzio, E.; Pezzoli, G.; Albertini, A.; Zecca, L. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: Consequences for neuronal vulnerability. J. Neural. Transm. 2006, 113, 757-767.
134. Faucheux, B. A.; Martin, M. E.; Beaumont, C.; Hauw, J. J.; Agid, Y.; Hirsch, E. C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 2003, 86, 1142-1148.
135. Double, K. L.; Gerlach, M.; Schunemann, V.; Trautwein, A. X.; Zecca, L.; Gallorini, M.; Youdim, M. B.; Riederer, P.; Ben-Shachar, D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 2003, 66, 489-494.
136. Ben-Shachar, D.; Riederer, P.; Youdim, M. B. Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease. J. Neurochem. 1991, 57, 1609-1614.
137. Gründemann, J.; Schlaudraff, F.; Liss, B. UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains. Methods Mol. Biol. 2011, 755, 363-374.
138. Matsuo, Y.; Kamitani, T. Parkinson's disease-related protein, β-synuclein, in malignant melanoma. PLoS ONE 2010, 5, e10481.
139. Fasano, M.; Giraudo, S.; Coha, S.; Bergamasco, B.; Lopiano, L. Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. Neurochem. Int. 2003, 42, 603-606.
140. Fedorow, H.; Halliday, G. M.; Rickert, C. H.; Gerlach, M.; Riederer, P.; Double, K. L. Evidence for specific phases in the development of human neuromelanin. Neurobiol. Aging 2006, 27, 506-512.
141. Chu, Y.; Kordower, J. H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis. 2007, 25, 134-149.
142. Double, K. L.; Ben-Shachar, D.; Youdim, M. B.; Zecca, L.; Riederer, P.; Gerlach, M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol. 2002, 24, 621-628.
143. Shamoto-Nagai, M.; Maruyama, W.; Yi, H.; Akao, Y.; Tribl, F.; Gerlach, M.; Osawa, T.; Riederer, P.; Naoi, M. Neuromelanin induces oxidative stress in mitochondria through release of iron: Mechanism behind the inhibition of 26S proteasome. J. Neural Transm. 2006, 113, 633-644.
144. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30, 244-250.
145. Webb, J. L.; Ravikumar, B.; Atkins, J.; Skepper, J. N.; Rubinsztein, D. C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278, 25009-25013.
146. Pan, T.; Zhu, J.; Hwu, W. J.; Jankovic, J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS ONE 2012, 7, e45183.
147. Zecca, L.; Zucca, F. A.; Costi, P.; Tampellini, D.; Gatti, A.; Gerlach, M.; Riederer, P.; Fariello, R. G.; Ito, S.; Gallorini, M.; et al. The neuromelanin of human substantia nigra: Structure, synthesis and molecular behaviour. J. Neural Transm. Suppl. 2003, 65, 145-155.
148. Wakamatsu, K.; Murase, T.; Zucca, F. A.; Zecca, L.; Ito, S. Biosynthetic pathway to neuromelanin and its aging process. Pigment Cell Melanoma Res. 2012, 25, 792-803.
149. Tessari, I.; Bisaglia, M.; Valle, F.; Samorì, B.; Bergantino, E.; Mammi, S.; Bubacco, L. The reaction of alpha-synuclein with tyrosinase: Possible implications for Parkinson disease. J. Biol. Chem. 2008, 283, 16808-16817.
150. Li, Y. H.; Gao, N.; Ye, Y. W.; Li, X.; Yu, S.; Yang, H.; Uéda, K.; Chan, P. β-Synuclein functions as a negative regulator for expression of tyrosine hudroxylase. Acta Neurol. Belg. 2011, 111, 130-135.
151. Koo, H. J.; Yang, J. E.; Park, J. H.; Lee, D.; Paik, S. R. β-Synuclein-mediated defense against oxidative stress via modulation of glutathione peroxidase. Biochim. Biophys. Acta 2013, 1834, 972-976.
152. Fornstedt, B.; Rosengren, E.; Carlsson, A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986, 25, 451-454.
153. Liang, C. L.; Nelson, O.; Yazdani, U.; Pasbakhsh, P.; German, D. C. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: Human midbrain dopamine neurons. J. Comp. Neurol. 2004, 473, 97-106.
154. Yu, S.; Zuo, X.; Li, Y.; Zhang, C.; Zhou, M.; Zhang, Y. A.; Uéda, K.; Chan, P. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci. Lett. 2004, 367, 34-39.
155. Abeliovich, A.; Schmitz, Y.; Fariñas, I.; Choi-Lundberg, D.; Ho, W. H.; Castillo, P. E.; Shinsky, N.; Verdugo, J. M.; Armanini, M.; Ryan, A.; et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25, 239-252.
156. Larsen, K. E.; Schmitz, Y.; Troyer, M. D.; Mosharov, E.; Dietrich, P.; Quazi, A. Z.; Savalle, M.; Nemani, V.; Chaudhry, F. A.; Edwards, R. H.; et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006, 26, 11915-11922.
157. Bellucci, A.; Navarria, L.; Falarti, E.; Zaltieri, M.; Bono, F.; Collo, G.; Spillantini, M. G.; Missale, C.; Spano, P. Redistribution of DAT/β-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS ONE 2011, 6, e27959.
158. Oaks, A. W.; Marsh-Armstrong, N.; Jones, J. M.; Credle, J. J.; Sidhu, A. Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS ONE 2013, 8, e70872.
159. Lotharius, J.; Brundin, P. Pathogenesis of Parkinson's disease: Dopamine, vesicles and β-synuclein. Nat. Rev. Neurosci. 2002, 3, 932-942.
160. Lotharius, J.; Barg, S.; Wiekop, P.; Lundberg, C.; Raymon, H. K.; Brundin, P. Effect of mutant β-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 2002, 277, 38884-38894.
161. Mosharov, E. V.; Staal, R. G.; Bove, J.; Prou, D.; Hananiya, A.; Markov, D.; Poulsen, N.; Larsen, K. E.; Moore, C. M.; Troyer, M. D.; et al. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 2006, 26, 9304-9311.
162. Chan, T.; Chow, A. M.; Cheng, X. R.; Tang, D. W.; Brown, I. R.; Kerman, K. Oxidative stress effect of dopamine on β-synuclein: Electroanalysis of solvent interactions. ACS Chem. Neurosci. 2012, 3, 569-574.